ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

SABS vs AGEN // RSI-14 & 200D SMA MOMENTUM

SAB Biotherapeutics Inc. (NASDAQ) VS. Agenus Inc. (NASDAQ) • 15-METRIC TALLY: SABS 3 — AGEN 1
▲ RSI-14 & 200D SMA MOMENTUM LEADER: SABS
rsi-technicals
59.0
rsi-technicals
46.9
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (SABS VS. AGEN) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC SABS AGEN SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin — 96.00% — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -27.40% -35.00% +7.60 SABS /roic <GO>
EV/EBITDA & P/E Valuation — — — TIE /valuation <GO>
Free Cash Flow Yield -15.55% -24.11% +8.56 SABS /fcf-yield <GO>
Operating Margin — -17.70% — TIE /operating-margins <GO>
Net Profit Margin — -2.70% — TIE /net-margins <GO>
Revenue Growth (YoY) — 10.40% — TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity 7.07 — — TIE /balance-sheet <GO>
Piotroski F-Score Quality 3/9 3/9 0.00 TIE /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum ACTIVE 59.0 46.9 +12.10 SABS /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple 20.6x — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $304.8M $308.9M -$4.1M AGEN /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR SABS REV AGEN REV SABS GROSS % AGEN GROSS % SABS FCF AGEN FCF
FY 2025 $137.1M $114.2M — 98.0% -$45.7M -$77.2M
FY 2024 $1.3M $103.5M — 98.0% -$34.6M -$158.9M
FY 2023 $2.2M $156.3M — — -$25.1M -$224.2M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
SABS // BETA —
AGEN // BETA —